Unnamed: 0,title,date,stock,sentiment
1379023.0,Xenon Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250M,2020-06-03 07:59:00-04:00,XENE,neutral
1379024.0,"Jefferies Assumes Xenon Pharmaceuticals at Buy, Raises Price Target to $23",2020-06-01 06:10:00-04:00,XENE,neutral
1379025.0,71 Biggest Movers From Friday,2020-05-26 04:30:00-04:00,XENE,neutral
1379026.0,46 Stocks Moving In Friday's Mid-Day Session,2020-05-22 12:45:00-04:00,XENE,neutral
1379027.0,"Xenon Pharmaceuticals Q1 EPS $(0.220) Beats $(0.320) Estimate, Sales $7.078M Beat $4.500M Estimate",2020-05-21 16:02:00-04:00,XENE,neutral
1379028.0,"The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive",2020-05-21 08:01:00-04:00,XENE,neutral
1379029.0,"The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows",2020-05-17 12:30:00-04:00,XENE,positive
1379030.0,Xenon Pharmaceuticals Says Cash And Equivalents Were ~$235M  At End Of Feb.,2020-03-31 08:32:00-04:00,XENE,neutral
1379031.0,"Wedbush Initiates Coverage On Xenon Pharmaceuticals with Outperform Rating, Announces $23 Price Target",2020-03-25 05:39:00-04:00,XENE,neutral
1379032.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,XENE,neutral
1379033.0,"Xenon Pharmaceuticals FY19 EPS $(1.54) Up From $(1.63) In FY18, Sales $6.829M",2020-03-09 16:02:00-04:00,XENE,neutral
1379034.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,XENE,negative
1379035.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,XENE,negative
1379036.0,52 Biggest Movers From Yesterday,2020-01-24 04:40:00-05:00,XENE,neutral
1379037.0,36 Stocks Moving In Thursday's Mid-Day Session,2020-01-23 14:05:00-05:00,XENE,neutral
1379038.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,XENE,neutral
1379039.0,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",2020-01-23 07:24:00-05:00,XENE,positive
1379040.0,36 Stocks Moving in Thursday's Pre-Market Session,2020-01-23 07:16:00-05:00,XENE,neutral
1379041.0,Xenon Pharmaceuticals Prices 3.75M Share Public Offering @$16/Share,2020-01-23 05:09:00-05:00,XENE,positive
1379042.0,26 Biotechnology Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:28:00-05:00,XENE,neutral
1379043.0,36 Healthcare Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:23:00-05:00,XENE,neutral
1379044.0,Xenon Pharmaceuticals Prices Public Offering of 3.75M Common Shares at $16.00/Share,2020-01-22 20:56:00-05:00,XENE,positive
1379045.0,Xenon Pharmaceuticals shares are trading lower after the company reported a common stock offering of no disclosed size.,2020-01-22 16:07:00-05:00,XENE,negative
1379046.0,"Xenon Pharma Reports Common Stock Offering, No Size Disclosed",2020-01-22 16:03:00-05:00,XENE,negative
1379047.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,XENE,neutral
1379048.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,XENE,negative
1379049.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,XENE,neutral
1379050.0,Stocks That Hit 52-Week Highs On Friday,2020-01-10 12:18:00-05:00,XENE,neutral
1379051.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,XENE,positive
1379052.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,XENE,neutral
1379053.0,"Benzinga's Top Upgrades, Downgrades For January 8, 2020",2020-01-08 10:56:00-05:00,XENE,positive
1379054.0,William Blair Initiates Coverage On Xenon Pharmaceuticals with Outperform Rating,2020-01-08 10:11:00-05:00,XENE,neutral
1379055.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,XENE,positive
1379056.0,Xenon Pharmaceuticals 13D Shows Neurocrine Biosciences Holds 5.4% Stake In Co.,2019-12-11 16:18:00-05:00,XENE,neutral
1379057.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,XENE,negative
1379058.0,Stocks That Hit 52-Week Highs On Tuesday,2019-12-10 14:27:00-05:00,XENE,neutral
1379059.0,Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at AES 2019,2019-12-07 14:56:00-05:00,XENE,neutral
1379060.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-12-05 12:07:00-05:00,XENE,neutral
1379061.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,XENE,positive
1379062.0,Stocks That Hit 52-Week Highs On Wednesday,2019-12-04 10:30:00-05:00,XENE,neutral
1379063.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,XENE,negative
1379064.0,63 Biggest Movers From Yesterday,2019-12-04 05:15:00-05:00,XENE,neutral
1379065.0,"The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial",2019-12-03 07:59:00-05:00,XENE,neutral
1379066.0,44 Stocks Moving In Monday's Mid-Day Session,2019-12-02 12:11:00-05:00,XENE,neutral
1379067.0,Stocks That Hit 52-Week Highs On Monday,2019-12-02 10:15:00-05:00,XENE,neutral
1379068.0,Xenon Pharmaceuticals shares are trading higher after the company received a $50 million upfront payment from Neurocrine Biosciences for the rights to its Xenon's XEN901.,2019-12-02 08:11:00-05:00,XENE,positive
1379069.0,Xenon to Receive $50M Upfront Payment From Neurocrine Biosciences for the Rights to Xenon's XEN901,2019-12-02 07:31:00-05:00,XENE,neutral
1379070.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-27 10:14:00-05:00,XENE,neutral
1379071.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,XENE,negative
1379072.0,60 Biggest Movers From Yesterday,2019-11-27 05:03:00-05:00,XENE,neutral
1379073.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-11-26 12:09:00-05:00,XENE,neutral
1379074.0,"Xenon Pharmaceuticals Q3 EPS $(0.33) Beats $(0.48) Estimate, Sales $3.5M",2019-11-05 16:24:00-05:00,XENE,neutral
1379075.0,"Benzinga's Top Upgrades, Downgrades For September 20, 2019",2019-09-20 09:47:00-04:00,XENE,positive
1379076.0,"Guggenheim Initiates Coverage On Xenon Pharmaceuticals with Buy Rating, Announces $25 Price Target",2019-09-20 07:18:00-04:00,XENE,neutral
1379077.0,"The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris",2019-09-10 07:36:00-04:00,XENE,neutral
1379078.0,Flexion Therapeutics And Xenon Pharmaceuticals Announce Flexion's Acquisition Of An Investigational NaV1.7 Inhibitor For The Treatment Of Post-Operative Pain; Xenon Received $3M Upfront And Is Eligible For Additional Milestones,2019-09-09 16:03:00-04:00,XENE,negative
1379079.0,Xenon Pharmaceuticals Q2 EPS $(0.37) Beats $(0.46) Estimate,2019-08-06 16:13:00-04:00,XENE,neutral
1379080.0,Xenon Pharmaceuticals Highlights Presentation Of Corporate Update On Neurology-Focused Pipeline At Jefferies 2019 Healthcare Conference,2019-06-05 08:12:00-04:00,XENE,neutral
1379081.0,Xenon Pharmaceuticals Announces Advancements In Neurology-Focused Pipeline And Anticipates Multiple Products In Phase 2 Or Later Stage Development This Year,2019-05-07 17:15:00-04:00,XENE,neutral
1379082.0,Xenon Pharmaceuticals Q1 EPS $(0.42) Misses $(0.36) Estimate,2019-05-07 17:15:00-04:00,XENE,negative
1379083.0,Stifel Nicolaus Assumes Xenon Pharmaceuticals at Buy,2019-03-29 09:24:00-04:00,XENE,neutral
1379084.0,Xenon Pharma FY18 EPS $(1.63) vs $(1.72) In FY17,2019-03-06 16:09:00-05:00,XENE,neutral
1379085.0,"The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split",2019-03-06 07:39:00-05:00,XENE,negative
1379086.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-03-03 09:41:00-05:00,XENE,neutral
1379087.0,Xenon Reports IND For XEN1101 Has Been Accepted; Site Selection And Patient Enrollment Underway In Canada And The United States For Xen1101 Phase 2b Clinical Trial,2019-01-28 08:06:00-05:00,XENE,positive
1379088.0,Xenon Granted FDA Rare Pediatric Disease Designation To XEN007 For Alternating Hemiplegia Of Childhood; Co. Eligible To Apply For Priority Review Voucher,2019-01-28 08:05:00-05:00,XENE,positive
1379089.0,58 Biggest Movers From Yesterday,2019-01-09 05:19:00-05:00,XENE,neutral
1379090.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-01-08 12:46:00-05:00,XENE,neutral
1379091.0,Xenon Pharmaceuticals Outlines 2019 Key Milestones,2019-01-07 04:07:00-05:00,XENE,neutral
1379092.0,Xenon Pharmaceuticals Inc. Reports XEN1101 CTA Accepted By Health Canada For Initiation Of Phase 2 Clinical Trial In Adult Focal Epilepsy; U.S. IND Filing Targeted In Q1 2019,2018-12-03 07:32:00-05:00,XENE,positive
1379093.0,"Xenon Pharmaceuticals Inc. Reports XEN1101 CTA Accepted By Health Canada For Initiation Of Phase 2 Clinical Trial In Adult Focal Epilepsy;
U.S. IND Filing Targeted In Q1 2019",2018-12-03 07:32:00-05:00,XENE,positive
1379094.0,"The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings",2018-11-25 09:41:00-05:00,XENE,neutral
1379095.0,Xenon Pharmaceuticals Q3 EPS $(0.63) Misses $(0.47) Estimate,2018-11-06 16:19:00-05:00,XENE,negative
1379096.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,XENE,positive
1379097.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,XENE,neutral
1379098.0,"The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx",2018-09-13 08:42:00-04:00,XENE,neutral
1379099.0,Xenon Pharmaceuticals 4.5M Share Public Offering of Common Shares @$14/Share,2018-09-12 20:53:00-04:00,XENE,positive
1379100.0,"Xenon Pharma Announces Common Stock Offering, No Size Disclosed",2018-09-12 16:03:00-04:00,XENE,negative
1379101.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,XENE,negative
1379102.0,Xenon Announces Agreement with Bausch Health to Buy Out Milestones and Royalties Related to its XEN1101 Program for $6M,2018-09-11 04:20:00-04:00,XENE,positive
1379103.0,"Stocks Which Set New 52-Week High Friday, September 7th",2018-09-10 16:36:00-04:00,XENE,neutral
1379104.0,52 Biggest Movers From Friday,2018-09-10 05:21:00-04:00,XENE,neutral
1379105.0,"Stocks That Made New 52-Week Highs Yesterday, September 6th",2018-09-07 16:47:00-04:00,XENE,neutral
1379106.0,44 Stocks Moving In Friday's Mid-Day Session,2018-09-07 12:54:00-04:00,XENE,neutral
1379107.0,Xenon Reports Expansion Of Its Ion Channel Product Pipeline With XEN496 For Potential Treatment Of Epilepsy,2018-09-06 06:36:00-04:00,XENE,neutral
1379108.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,XENE,neutral
1379109.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,XENE,neutral
1379110.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,XENE,positive
1379111.0,"Stocks Which Set New 52-Week High Yesterday, August 29th",2018-08-30 11:47:00-04:00,XENE,neutral
1379112.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,XENE,neutral
1379113.0,Xenon Announces XEN1101 Pharmacodynamic Data From Phase 1b TMS Study For Treatment Of Epilepsy; XEN1101 Demonstrated Statistically Significant Reduction In Corticospinal And Cortical Excitability,2018-08-29 06:14:00-04:00,XENE,positive
1379114.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results",2018-08-26 15:40:00-04:00,XENE,neutral
1379115.0,"Stocks Which Set New 52-Week High Yesterday, August 21st",2018-08-22 09:06:00-04:00,XENE,neutral
1379116.0,"Stocks Which Set New 52-Week High Tues., Aug. 21, 2018",2018-08-21 14:50:00-04:00,XENE,neutral
1379117.0,"Stocks Which Set New 52-Week High Yesterday, August 14th",2018-08-15 12:29:00-04:00,XENE,neutral
1379118.0,"Stocks Which Set New 52-Week High Yesterday, August 9th",2018-08-10 10:03:00-04:00,XENE,neutral
1379119.0,"The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss",2018-08-10 07:38:00-04:00,XENE,negative
1379120.0,"Stocks Which Set New 52-Week High Yesterday, August 8th",2018-08-09 11:03:00-04:00,XENE,neutral
1379121.0,Xenon Pharmaceuticals Q2 EPS $(0.45) Beats $(0.49) Estimate,2018-08-07 16:46:00-04:00,XENE,neutral
1379122.0,Xenon Pharma 8-K Shows Co. Entered ATM Equity Offering For $50M In Common Shares,2018-07-12 06:13:00-04:00,XENE,positive
1379123.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,XENE,neutral
1379124.0,20 Stocks Moving In Tuesday's Pre-Market Session,2018-07-03 08:04:00-04:00,XENE,neutral
1379125.0,"Seeing Notable Block Trade In Xenon Pharmaceuticals; 1M Shares at $9, Below Bid of $9.10",2018-06-29 14:28:00-04:00,XENE,negative
1379126.0,Xenon Pharmaceuticals Receives Orphan Drug Designation From FDA,2018-06-25 13:02:00-04:00,XENE,neutral
1379127.0,"Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi",2018-06-14 08:11:00-04:00,XENE,negative
1379128.0,"Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111",2018-06-13 07:48:00-04:00,XENE,negative
1379129.0,42 Biggest Movers From Yesterday,2018-06-13 05:31:00-04:00,XENE,neutral
1379130.0,41 Stocks Moving In Tuesday's Mid-Day Session,2018-06-12 12:29:00-04:00,XENE,neutral
1379131.0,26 Stocks Moving In Tuesday's Pre-Market Session,2018-05-29 08:13:00-04:00,XENE,neutral
1379132.0,26 Stocks Moving In Wednesday's Pre-Market Session,2018-05-16 08:14:00-04:00,XENE,neutral
1379133.0,"Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings",2018-05-16 08:10:00-04:00,XENE,neutral
1379134.0,45 Biggest Movers From Yesterday,2018-05-16 06:01:00-04:00,XENE,neutral
1379135.0,7 Stocks Moving In Tuesday's After-Hours Session,2018-05-15 17:14:00-04:00,XENE,neutral
1379136.0,Xenon Pharma Shares Up 11.7% On Earlier Report Of FAvorable PK Profile For XEN901 In Its Phase 1 Study,2018-05-15 14:10:00-04:00,XENE,positive
1379137.0,37 Stocks Moving In Tuesday's Mid-Day Session,2018-05-15 12:32:00-04:00,XENE,neutral
1379138.0,"Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway",2018-05-15 08:44:00-04:00,XENE,positive
1379139.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-05-15 08:06:00-04:00,XENE,neutral
1379140.0,Xenon Presents XEN901 Phase 1 Clinical Update Demonstrating Favorable PK Profile,2018-05-15 06:09:00-04:00,XENE,positive
1379141.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-13 10:06:00-04:00,XENE,neutral
1379142.0,Xenon Pharmaceuticals Q1 EPS $(0.21) Beats $(0.48) Estimate,2018-05-08 16:03:00-04:00,XENE,neutral
1379143.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,XENE,neutral
1379144.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,XENE,neutral
1379145.0,"Xenon Pharma Reports FY17 EPS $(1.72) vs $(1.49) Est., Sales $311K vs $4.6M Est.",2018-03-07 16:38:00-05:00,XENE,neutral
1379146.0,Xenon Pharmaceuticals Q4 Earnings Outlook,2018-03-07 09:58:00-05:00,XENE,neutral
1379147.0,32 Biggest Movers From Yesterday,2018-03-06 05:08:00-05:00,XENE,neutral
1379148.0,45 Biggest Movers From Yesterday,2018-03-02 05:03:00-05:00,XENE,neutral
1379149.0,Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Start of XEN901 Phase 1 Clinical Trial,2018-02-20 08:36:00-05:00,XENE,neutral
1379150.0,44 Biggest Movers From Friday,2018-02-12 05:01:00-05:00,XENE,neutral
1379151.0,32 Biggest Movers From Yesterday,2017-12-27 04:59:00-05:00,XENE,neutral
1379152.0,Shares Of Xenon Pharmaceuticals Up 15% As Meg Tirrell Published An Article Titled 'Rare genes yield new hope for managing pain without opioids' Mentioning The Company,2017-11-17 14:25:00-05:00,XENE,positive
1379153.0,57 Biggest Movers From Yesterday,2017-11-09 05:16:00-05:00,XENE,neutral
1379154.0,"Xenon Pharma Reports Q3 EPS $(0.43) vs. $(0.51) In Same Qtr. Last Year, Sales 264K vs. $413K YoY",2017-11-07 17:59:00-05:00,XENE,neutral
1379155.0,Xenon Pharma Initiates XEN1101 Phase 1 Clinical Trial,2017-10-17 08:32:00-04:00,XENE,neutral
1379157.0,Mid-Afternoon Market Update: NASDAQ Down 1.1%; Handy & Harman Shares Spike Higher,2017-06-27 14:34:00-04:00,XENE,positive
1379158.0,15 Biggest Mid-Day Losers For Tuesday,2017-06-27 12:55:00-04:00,XENE,negative
1379159.0,Mid-Day Market Update: Crude Oil Up Over 2%; Xenon Pharmaceuticals Shares Slide,2017-06-27 12:18:00-04:00,XENE,negative
1379160.0,Mid-Morning Market Update: Markets Open Lower; EU Slaps Google Parent Alphabet With $2.7 Billion Fine,2017-06-27 10:23:00-04:00,XENE,negative
1379161.0,"Xenon Pharma Shares Resume Trade, Fall ~22%",2017-06-27 08:45:00-04:00,XENE,positive
1379162.0,Xenon Pharma Shares To Resume Trade At 8:45 a.m. EDT,2017-06-27 08:19:00-04:00,XENE,positive
1379163.0,"UPDATE: Xenon Pres, CEO, Simon Pimstone, Says '...Xenon remains focused on advancing its pipeline of neurology-related development candidates, with multiple programs anticipated to enter clinical development in 2017'",2017-06-27 08:16:00-04:00,XENE,positive
1379164.0,"Teva, Xenon Pharma Report Results From Phase II Study Of TV-45070 In Patients With PHN: Did Not Meet Primary, Secondary Endpoints",2017-06-27 08:16:00-04:00,XENE,neutral
1379165.0,Xenon Pharma Shares Halted News Pending,2017-06-27 08:10:00-04:00,XENE,positive
1379166.0,"Xenon Pharmaceuticals 10%+ Mark H. Lampert Buys 26,408 @ Avg Price: $3.84 -Form4",2017-06-20 04:59:00-04:00,XENE,neutral
1379167.0,"Xenon Pharmaceuticals 10%+ Owner Mark N Lampert Buys 358,698 @ Avg Price: $3.81 -Form 4",2017-06-08 20:49:00-04:00,XENE,neutral
1379168.0,"Xenon Pharmaceuticals Reports Q1 EPS $(0.43) vs $(0.38) Est., Sales $16K vs $300K Est.",2017-05-09 17:10:00-04:00,XENE,neutral
1379169.0,Xenon Acquires New Potassium Channel Modulator for the Treatment of Epilepsy,2017-04-26 06:53:00-04:00,XENE,neutral
1379170.0,Mid-Afternoon Market Update: Dow Falls 50 Points; Micron Shares Jump Following Strong Earnings Report,2017-03-24 14:46:00-04:00,XENE,positive
1379171.0,12 Biggest Mid-Day Losers For Friday,2017-03-24 13:18:00-04:00,XENE,negative
1379172.0,Mid-Day Market Update: ZAIS Group Gains Following Q4 Results; Xenon Pharmaceuticals Shares Decline,2017-03-24 12:53:00-04:00,XENE,positive
1379173.0,Mid-Morning Market Update: Markets Open Higher; Finish Line Earnings Miss Expectations,2017-03-24 10:16:00-04:00,XENE,negative
1379174.0,Xenon Phamraceuticals On Conf. Call Says Co. Did Not Plan Expenses For Mid-Stage Study Of XEN801,2017-03-24 09:03:00-04:00,XENE,neutral
1379175.0,16 Stocks Moving In Friday's Pre-Market Session,2017-03-24 08:35:00-04:00,XENE,neutral
1379176.0,Xenon Pharma's XEN801 Did Not Meet Efficacy Enpoints in Phase 2 Trial,2017-03-24 06:30:00-04:00,XENE,neutral
1379177.0,"Benzinga's Top Upgrades, Downgrades For March 13, 2017",2017-03-13 09:34:00-04:00,XENE,positive
1379178.0,"Jefferies Assumes Xenon Pharmaceuticals Inc. With Buy, Announces $13 Price Target",2017-03-13 06:23:00-04:00,XENE,neutral
1379179.0,"Xenon Pharma Reports Q4 EPS $(1.48) May Not Compare To $(0.42) Est., Sales $1.803M vs $480K Est.",2017-03-08 16:22:00-05:00,XENE,neutral
1379180.0,Xenon Pharmaceuticals Says Topline Results from XEN801 Phase 2 Clinical Trial are Expected in Latter Part of Q1 of 2017.,2017-01-08 21:33:00-05:00,XENE,neutral
1379181.0,Xenon Pharmaceuticals Reports Q3 EPS $(0.51) vs. Est. $(0.43),2016-11-03 17:07:00-04:00,XENE,neutral
1379182.0,Benzinga's Top Initiations,2016-10-21 09:23:00-04:00,XENE,positive
1379183.0,Stifel Nicolaus Initiates Coverage On Xenon Pharmaceuticals Inc. - Common Shares at Buy,2016-10-21 07:28:00-04:00,XENE,positive
1379184.0,"The Market In 5 Minutes: Oil, Debates And Epidiolex",2016-09-26 09:04:00-04:00,XENE,neutral
1379185.0,"Guggenheim Securities Initiates Coverage on Xenon Pharmaceuticals at Buy, Announces $20.00 PT",2016-09-26 06:31:00-04:00,XENE,positive
1379186.0,Xenon Pharmaceuticals Prices $30M Offering Of Shares,2016-09-08 09:03:00-04:00,XENE,positive
1379187.0,Xenon Pharmaceuticals Proposes Shelf Offering Of Common Shares,2016-09-07 16:33:00-04:00,XENE,positive
1379188.0,Xenon Pharmaceuticals Reports Q2 EPS $(0.42) vs. Est. $(0.48),2016-08-03 16:40:00-04:00,XENE,neutral
1379189.0,"Xenon Expects XEN801 Results In Q1 2017, Delayed One Quarter",2016-08-03 16:17:00-04:00,XENE,negative
1379190.0,"Xenon Pharmaceuticals Presents Corporate Update and Highlights Its Proprietary Therapeutic Programs, Will File IND In 1H 2017 For Nav1.6",2016-06-08 07:46:00-04:00,XENE,neutral
1379191.0,Stocks Hitting 52-Week Lows,2016-05-27 10:28:00-04:00,XENE,negative
1379192.0,"Xenon Pharma Will Offer Business, Milestone Update at Needham Conference",2016-03-31 16:30:00-04:00,XENE,neutral
1379193.0,Teva Reports 7.7% Stake in Xenon Pharmaceuticals in 13G,2016-03-30 06:06:00-04:00,XENE,neutral
1379194.0,"Xenon, Genentech Extend Partnerships Focused on Pain",2016-03-15 08:03:00-04:00,XENE,neutral
1379195.0,"Jefferies Maintains Buy on Xenon Pharmaceuticals, Lowers PT to $11.00",2016-03-09 08:18:00-05:00,XENE,negative
1379196.0,"Xenon Pharmaceuticals Reports FY15 EPS $(1.10) vs. Prior Year Quarter $4.11, Rev. $15.5M vs. Prior Year Quarter $28.3M",2016-03-08 16:00:00-05:00,XENE,neutral
1379197.0,Xenon Begins Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne,2016-02-10 08:01:00-05:00,XENE,neutral
1379198.0,"S-3 from Xenon Pharma Shows Registration for $150M Mixed Securities Shelf Offering, Selling Holders Offering ~4.39M Shares of Common Stock",2015-12-07 17:34:00-05:00,XENE,positive
1379199.0,"Xenon Pharmaceuticals Reports Q3 EPS $(0.27) vs. Est. $(0.02), Rev. $4.293M vs. Est. $4.65M",2015-11-10 16:31:00-05:00,XENE,neutral
1379200.0,Xenon Pharma Reports Initiation of XEN801 Phase 1 Trial,2015-09-24 08:37:00-04:00,XENE,neutral
1379201.0,Xenon Pharmaceuticals Reaches Milestone in Genentech Collaboration to Discover Novel Pain Targets; Triggers Payment,2015-09-21 08:30:00-04:00,XENE,negative
1379202.0,"8-K from Xenon Pharma Shows Co. Determined Restatement of Financial Statements Required for Qtr. Period Ended Mar. 31, '15",2015-08-13 16:59:00-04:00,XENE,positive
1379203.0,Xenon Pharma. Reports Q2 EPS $(0.07) vs. Est. $(0.16),2015-08-10 16:45:00-04:00,XENE,neutral
1379204.0,"Wednesday's Mid-Day Movers: Chubb, Rock Creed, RADA Win; Peabody Energy, Ballard Fall",2015-07-01 13:44:00-04:00,XENE,positive
1379205.0,Morning Market Losers,2015-07-01 09:52:00-04:00,XENE,negative
1379206.0,"Shares of Xenon Pharma Resume Trade, Now Down 35%",2015-07-01 08:40:00-04:00,XENE,positive
1379207.0,Shares of Xenon Pharma to Resume Trade at 8:30 a.m. EDT,2015-07-01 08:08:00-04:00,XENE,positive
1379208.0,"Teva, Xenon Provides Update on TV-45070 Phase 2b Study in Osteoarthritis Pain",2015-07-01 08:03:00-04:00,XENE,negative
1379209.0,Xenon Pharma Shares Halted News Pending,2015-07-01 07:55:00-04:00,XENE,positive
1379210.0,Xenon Pharma Reports Q1 EPS $(0.30) vs. Est. $0.14; Estimates May Not Compare,2015-05-12 16:01:00-04:00,XENE,neutral
1379211.0,Top 4 Small-Cap Stocks In The Biotechnology Industry With The Highest Profit Margin,2015-04-29 04:50:00-04:00,XENE,positive
1379212.0,Analyst Points At 3 Upcoming Biotech Lock-Up Expirations,2015-04-17 08:53:00-04:00,XENE,neutral
1379213.0,"Teva, Xenon Reports Enrollment of First Patient in Phase 2b Study of TV-45070 for PHN",2015-04-02 08:00:00-04:00,XENE,neutral
1379214.0,Xenon Pharmaceuticals' Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia,2015-02-19 17:02:00-05:00,XENE,neutral
1379215.0,Benzinga's Volume Movers,2014-12-30 10:39:00-05:00,XENE,neutral
1379216.0,"Cam Initiates Coverage on Xenon Pharmaceuticals  at Buy, Announces $15.00 PT",2014-12-02 06:32:00-05:00,XENE,neutral
1379217.0,Traders in Xenon Pharma Selling Despite Two New Positive Ratings from Jefferies and Wells Fargo; Stock Down 7+%,2014-12-01 10:15:00-05:00,XENE,negative
1379218.0,UPDATE: Jefferies Initiates Coverage On Xenon Pharmaceuticals On Multiple Positive Factors,2014-12-01 10:05:00-05:00,XENE,positive
1379219.0,Xenon Pharmaceuticals Announces Closing Of Initial Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares,2014-11-10 16:12:00-05:00,XENE,positive
1379220.0,Expected IPOs For November 5,2014-11-05 09:19:00-05:00,XENE,neutral
1379221.0,Xenon Pharmaceuticals Prices $4M Share IPO @$9.00/Share,2014-11-04 20:27:00-05:00,XENE,positive
1379222.0,Expected IPOs For October 17,2014-10-17 09:13:00-04:00,XENE,neutral
1379223.0,Xenon Pharmaceuticals Expects 4M Share IPO to Price $10.00-$12.00/Share,2014-10-06 06:09:00-04:00,XENE,positive
1379224.0,Xenon Pharmaceuticals Inc Files for Up to $51.8M IPO ,2014-09-10 06:05:00-04:00,XENE,neutral
